查詢結果分析
來源資料
相關文獻
- Treatment of Adolescent and Young Adult Acute Lymphoblastic Leukemia with the Pediatric Protocol: Results from a Single Institution in Taiwan
- Development of Acute Lymphoblastic Leukemia in a Child after Treatment of Langerhans Cell Histiocytosis: Report of One Case
- 成年急性淋巴性白血病之現況
- Genetic Studies in Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia in Young Adults: Two Chemotherapeutic Protocols for the Treatment of 46 Patients
- Intelligence Quotient in Childhood Acute Lymphoblastic Leukemia after Prophylactic Treatment in Central Nervous System with 18 Gy Cranial Irradiation and Intrathecal Methotrexate
- Acute Lymphoblastic Leukemia Occurring as a Second Malignant Neoplasm in a Child
- 照顧一位急性淋巴性白血病學齡期兒童的護理經驗
- 成人型急性淋巴性白血病復發以視神經病變為初始表徵--病例報告
- Allogeneic Bone Marrow Transplantation for Children with Acute Lymphoblastic Leukemia in Second Remission or Relapse
頁籤選單縮合
題名 | Treatment of Adolescent and Young Adult Acute Lymphoblastic Leukemia with the Pediatric Protocol: Results from a Single Institution in Taiwan=使用兒童急性淋巴性白血病療程來治療青少年及年輕成人患者:臺灣單一醫學中心的成效 |
---|---|
作者姓名(中文) | 林瑛珠; 滕傑林; 楊陽生; 王任卿; 張光喜; 黃文豊; | 書刊名 | 臺灣癌症醫學雜誌 |
卷期 | 1:1 2014.06[民103.06] |
頁次 | 頁28-38 |
分類號 | 415.635 |
關鍵詞 | 青少年及年輕成人; 急性淋巴性白血病; 兒童療程; AYA; ALL; mTPOG; |
語文 | 英文(English) |
中文摘要 | 背景:對於使用兒童急性淋巴性白血病療程來治療青少年及年輕成人患者的成果,在台 灣仍是未知數。所以我們進行病例對照研究來探討使用兒童急性淋巴性白血病療程來治 療青少年及年輕成人患者其無病存活、整體存活及相關併發症。 方法:以病例回顧的方式探討。共分析 23 例罹患急性淋巴性白血病的青少年及年輕成人 患者。其中有 8 位使用修正後的兒童急性淋巴性白血病療程(mTPOG),另 23 位使用 CALGB 8811 治療。 結果:使用 mTPOG 及 CALGB 8811 治療患者的 1 年無病存活率分別為 100%及 33.3% (p=0.016),2 年無病存活率分別 100%及 22.2% (=0.006)。二組的 1 年整體存活率分別為 100%及 37% (p=0.013),2 年整體存活率為 100%及 22% (p=0.003)。 結論:我們的結果顯示罹患急性淋巴球性白血病青少年及年輕成人患者以修正後的兒童 急性淋巴性白血病療程(mTPOG)治療能提供比 CALGB 8811 治療有更高的存活率。 |
英文摘要 | Background: It remains unclear whether pediatric protocols provide a better outcome to adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) than adult protocols in Taiwan. Therefore, we conducted a case-control study to compare the outcome events, disease-free survival (DFS), and overall survival (OS) in Taiwanese AYA patients receiving either pediatric or adult ALL protocols. Methods: Twenty-three Taiwanese AYA patients with ALL were retrospectively reviewed: eight patients received the pediatric ALL protocol modified from the Taiwan Pediatric Oncology Group (mTPOG) regimen, and 15 were treated by using the Cancer and Leukemia Group B study 8811 (CALGB-8811) regimen. Results: The DFS rates for patients in the mTPOG and CALGB-8811 groups were 100% versus 33.3% (p = 0.016) at one year, and 100% versus 22.2% (p = 0.006) at two years, respectively. The OS rates for patients in mTPOG and CALGB-8811 groups were 100% versus 37.0% (p = 0.013) at one year, and 100% versus 22.2% (p = 0.003) at two years, respectively. Conclusions: Our results suggested that the pediatric mTPOG protocol provides AYA ALL patients a better DFS and OS than the adult CALGB-8811 protocol. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。